Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Leukemia, B-Cell × Observation × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 7 Leukemia, Myeloid, Acute 4 Neoplasm Metastasis 3 Lung Neoplasms 3 Endometrial Neoplasms 3 Colonic Neoplasms 3 Breast Neoplasms 3 Sarcoma 2 Oropharyngeal Neoplasms 2 Neuroblastoma 2 Melanoma 2 Leukemia, Myelomonocytic, Acute 2 Leukemia, Monocytic, Acute 2 Leukemia, Megakaryoblastic, Acute 2 Leukemia, Erythroblastic, Acute 2 Colorectal Neoplasms 2 Carcinoma, Hepatocellular 2 Brain Neoplasms 2 Anus Neoplasms 2 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Intraepithelial Lesions 1 Smoldering Multiple Myeloma 1 Sarcoma, Synovial 1 Sarcoma, Alveolar Soft Part 1 Pleuropulmonary blastoma 1 Pathologic Complete Response 1 Papillomavirus Infections 1 Pancreatic Neoplasms 1

Interventions

ofatumumab 3 venetoclax 2 obinutuzumab 2 ibrutinib 2 Chlorambucil 2 pirtobrutinib 1 acalabrutinib 1 Tablets 1 Observation 1 Cholecalciferol 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01039376 2019-07-30

PROLONG

Novartis

Phase 3 Terminated

480 enrolled 30 charts

LymphoidOther hematologic neoplasm

Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡